CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向乳腺癌的 CAR-T 细胞免疫治疗
英文原题：Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer.
查看英文原题
Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
redirected嵌合抗原受体（CAR）T细胞能够以主要组织相容性复合体非依赖的方式识别并清除癌细胞。通过CAR表达对T细胞进行基因工程改造，在血液系统恶性肿瘤治疗中相比实体瘤已取得显著成果。由于其在靶向实体瘤方面成功有限，人们一直在努力增强这些活体药物的有效性。T细胞迁移不良、肿瘤特异性抗原选择以及免疫抑制性肿瘤微环境被认为是CAR-T 细胞靶向实体瘤的主要障碍。在此，我们综述了CAR-T 细胞疗法在乳腺癌（全球女性第二大癌症相关死亡原因）中的现状，以及为控制CAR-T 细胞主要局限性而采用的一些策略。此外，我们总结了为提高该疗法在靶向实体瘤中的治疗结局而开发的各种方法。
展开英文摘要原文
Redirected chimeric antigen receptor (CAR) T-cells can recognize and eradicate cancer cells in a major histocompatibility complex independent manner. Genetic engineering of T cells through CAR expression has yielded great results in the treatment of hematological malignancies compared with solid tumors.
There has been a constant effort to enhance the effectiveness of these living drugs, due to their limited success in targeting solid tumors. Poor T cell trafficking, tumor-specific antigen selection, and the immunosuppressive tumor microenvironment are considered as the main barriers in targeting solid tumors by CAR T-cells.
Here, we reviewed the current state of CAR T-cell therapy in breast cancer, as the second cancer-related death in women worldwide, as well as some strategies adopted to keep the main limitations of CAR T-cells under control. Also, we summarized various approaches that have been developed to enhance the therapeutic outcomes of this treatment in solid tumors targeting.
论文信息
- 作者
- Rahimmanesh I、Khanahmad H
- 第一作者单位
- Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.Iran
- 通讯作者单位
- Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.Iran
- 文献类型
- 综述
- 期刊
- Research in pharmaceutical sciences2021 Oct
- 原文标识
- PubMed 34522192 · DOI 10.4103/1735-5362.323911
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →